A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab

BACKGROUND: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of cholesterol-lowering medications that provide significant reductions in lipids but at a large cost relative to statins. With 2 such drugs now on the market, alirocumab and evolocumab, comparing the ev...

Descripción completa

Detalles Bibliográficos
Autores principales: McDonagh, Marian, Peterson, Kim, Holzhammer, Brittany, Fazio, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2016
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397903/
https://www.ncbi.nlm.nih.gov/pubmed/27231792
http://dx.doi.org/10.18553/jmcp.2016.22.6.641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397903/
https://www.ncbi.nlm.nih.gov/pubmed/27231792
http://dx.doi.org/10.18553/jmcp.2016.22.6.641

Ejemplares similares